Literature DB >> 12112046

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis.

Catherine M Dalton1, Peter A Brex, Katherine A Miszkiel, Simon J Hickman, David G MacManus, Gordon T Plant, Alan J Thompson, David H Miller.   

Abstract

Traditionally, multiple sclerosis (MS) has been diagnosed on the basis of clinical evidence of dissemination in time and space. Previously, it could not be diagnosed in patients with single clinical episodes of demyelination known as clinically isolated syndromes. New diagnostic criteria from the International Panel of McDonald and colleagues incorporate MRI evidence of dissemination in time and space to allow a diagnosis of MS in patients with clinically isolated syndromes. From clinical and MRI examinations performed prospectively at baseline, 3 months, 1 year, and 3 years of follow-up, the frequency of developing MS was ascertained by the application of both the new McDonald criteria and the Poser criteria for clinically definite MS. The specificity, sensitivity, positive and negative predictive value, and accuracy of the new criteria for the development of clinically definite MS were assessed. At 3 months, 20 of 95 (21%) patients had MS with the McDonald criteria, whereas only 7 of 95 (7%) had developed clinically definite MS. After 1 year, the corresponding figures were 38 of 79 (48%) and 16 of 79 (20%), and after 3 years, they were 29 of 50 (58%) and 19 of 50 (38%). The development of MS with the new MRI criteria after 1 year had a high sensitivity (83%), specificity (83%), positive predicative value (75%), negative predictive value (89%), and accuracy (83%) for clinically definite MS at 3 years. Use of the new McDonald criteria more than doubled the rate of diagnosis of MS within a year of presentation with a clinically isolated syndrome. The high specificity, positive predictive value, and accuracy of the new criteria for clinically definite MS support their clinical relevance.

Entities:  

Mesh:

Year:  2002        PMID: 12112046     DOI: 10.1002/ana.10240

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  51 in total

Review 1.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Escalating immunotherapy of multiple sclerosis.

Authors:  Peter Rieckmann; Anthony Traboulsee; Virginia Devonshire; Joel Oger
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

3.  Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis?

Authors:  M P Wattjes; M Harzheim; C K Kuhl; J Gieseke; S Schmidt; L Klotz; T Klockgether; H H Schild; G G Lutterbey
Journal:  AJNR Am J Neuroradiol       Date:  2006-09       Impact factor: 3.825

4.  Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T.

Authors:  Mike P Wattjes; Götz G Lutterbey; Michael Harzheim; Jürgen Gieseke; Frank Träber; Luisa Klotz; Thomas Klockgether; Hans H Schild
Journal:  Eur Radiol       Date:  2006-04-29       Impact factor: 5.315

Review 5.  Multiple sclerosis: new insights and trends.

Authors:  M Inglese
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

6.  Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis.

Authors:  Tijmen Korteweg; Bernard M J Uitdehaag; Dirk L Knol; Robin H M Smithuis; Paul R Algra; Cees de Vries; Peter A Poppe; Jan-Hein T M van Waesberghe; Elisabeth Bergers; Geert J Lycklama à Nijeholt; Chris H Polman; Frederik Barkhof
Journal:  Eur Radiol       Date:  2006-05-18       Impact factor: 5.315

7.  [Revision of McDonald's new diagnostic criteria for multiple sclerosis].

Authors:  H Wiendl; B C Kieseier; R Gold; R Hohlfeld; M Bendszus; H-P Hartung
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

Review 8.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

Authors:  J H Simon; D Li; A Traboulsee; P K Coyle; D L Arnold; F Barkhof; J A Frank; R Grossman; D W Paty; E W Radue; J S Wolinsky
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

10.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.